Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

February 27, 2019

Study Completion Date

March 20, 2019

Conditions
Atopic Dermatitis Eczema
Interventions
BIOLOGICAL

B244

B244 suspension

BIOLOGICAL

Vehicle

Vehicle suspension

Trial Locations (17)

19103

Paddington Testing Co., Philadelphia

31904

Columbus Regional Research Institute, Columbus

32256

Clinical Neuroscience Solution, Inc, Jacksonville

32801

Clinical Neuroscience Solution, Inc, Orlando

33012

Neostart Corporation d.b.a AGA Clinical Trials, Hialeah

33027

FXM Research Miramar, Miramar

33175

FXM Research Corp., Miami

33607

Clinical Research Trials of Florida, Inc., Tampa

35205

Central Research Associates, Birmingham

48349

Clarkston Skin Research, Clarkston

60611

DeNova Research dba Arano, LLC, Chicago

64506

MediSearch Clinical Trials, Saint Joseph

73071

Central Sooner Research, Norman

85018

Elite Clinical Studies, Phoenix

87108

LoveLace Scientific Resources, Albuquerque

91436

Encino Research Center, Encino

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Veristat, Inc.

OTHER

lead

AOBiome LLC

INDUSTRY